Skip to main content
HR 6731 116th Congress House Government Operations and Politics Manufacturing Prescription drugs Public contracts and procurement Trade agreements and negotiations

Securing America’s Pharmaceutical Supply Chain Act

Introduced: May 19, 2020 Introduced by: Stauber, Pete Republican · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 5, 2020
Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 5, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Securing America's Pharmaceutical Supply Chain Act

This bill allows an executive agency to purchase a drug approved or licensed by the Food and Drug Administration only if the drug is over 50% sourced, manufactured, and assembled in the United States.

This requirement may be waived (1) if the drug is not available in sufficient quantity or quality as over 50% sourced, manufactured, and assembled in the United States; or (2) during an emergency.

The U.S. Trade Representative (USTR) shall modify U.S. product coverage under all free trade agreements and the World Trade Organization Agreement on Government Procurement to exclude coverage of essential medicines and medical countermeasures. Subsequent to such modifications, the USTR shall make any necessary corresponding modifications of existing waivers and notify the Office of Management and Budget.

What's happening now May 5, 2020

Referred to the Committee on Oversight and Reform, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Democratic 1
Gibbs, Bob
· May 19, 2020
Hagedorn, Jim
· May 19, 2020
 D
Garamendi, John
California · May 5, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6731: Securing America’s Pharmaceutical Supply Chain Act. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6731/
MLA
"H.R. 6731: Securing America’s Pharmaceutical Supply Chain Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6731/.
Bluebook (legal)
H.R. 6731, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6731/.
Markdown link
[H.R. 6731: Securing America’s Pharmaceutical Supply Chain Act](https://openamerica.io/bill/116-HR-6731/)
Report a problem